This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the decision support tool works to enhance germline genetic testing in patients with prostate cancer. Germline genetic testing is a guideline-recommended standard of care for many patients with prostate cancer. Completing genetic testing can enable the use of targeted therapies, offers access to novel clinical trials, provides valuable information, and can help identify at risk family members. The decision support tool may educate patients and assist in the decision to engage with germline genetic testing.
Diagnosed prostate cancer patients receiving care at Lyndon B. Johnson (LBJ) Hospital
Were recommended for germline genetic testing by their oncology provider
Can provide informed consent
Can communicate in English or Spanish
Prostate cancer patients receiving care at LBJ who are unable to participate due to a serious psychological or cognitive condition
Sequential
Behavioral Intervention
BehavioralView decision support tool
Biospecimen Collection
Procedure/SurgeryUndergo blood sample collection
Electronic Health Record Review
Other interventionAncillary studies
Genetic Counseling
Other interventionMeet with genetic counselor
Genetic Testing
Other interventionUndergo standard of care genetic testing
Interview
Other interventionComplete qualitative interview
Interview
Other interventionComplete cognitive interview
Survey Administration
Other interventionAncillary studies
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Click on the lead sponsor to view all of their trials.
